Clinical Trials Logo

Allergic Rhinoconjunctivitis clinical trials

View clinical trials related to Allergic Rhinoconjunctivitis.

Filter by:

NCT ID: NCT01535118 Completed - Clinical trials for Allergic Rhinoconjunctivitis

A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)

AIRS
Start date: January 2012
Phase: N/A
Study type: Observational

This study will gather information on allergic rhinoconjunctivitis from surveys completed by adults and children.

NCT ID: NCT01490411 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis

Start date: October 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if rBet v1-FV works to relieve Seasonal Allergic Rhinitis symptoms compared to Placebo (an inactive substance that looks like rBet v1-FV and also contains Aluminum Hydroxide but does not contain the experimental drug). rBet v1-FV is a vaccine that works by exposing your immune system to something that resembles birch. This vaccine may help to lessen your allergy symptoms during the natural birch season.

NCT ID: NCT01489033 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense

Start date: January 2010
Phase: Phase 1
Study type: Interventional

Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic disease the aim of this study was to assess safety and tolerability of three different subcutaneous immunotherapy dose escalations in patients allergic to the pollen of Phleum pratense.

NCT ID: NCT01489020 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)

Start date: January 2011
Phase: Phase 1
Study type: Interventional

Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic diseases the aim of this study was to assess safety and tolerability of 3 different subcutaneous immunotherapy dose escalations in patients allergic to Dermatophagoides pteronyssinus.

NCT ID: NCT01466465 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Vitamin D and Grass Pollen Specific Immunotherapy

Start date: October 2011
Phase: Phase 2
Study type: Interventional

Allergen-specific immunotherapy is the only causal therapy of Immunoglobulin E-induced allergies like allergic rhinoconjunctivitis. Despite progress during the last decades it is limited by a long treatment time and high non-responder frequency. Based on experimental and epidemiological evidences we hypothesize that vitamin D can act as an effective immunomodulatory adjuvant to overcome these limitations.

NCT ID: NCT01454531 Completed - Clinical trials for Allergic Rhinoconjunctivitis

An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy

Start date: June 2011
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to assess the tolerability of AVANZ.

NCT ID: NCT01438827 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Avanz Phleum Pratense Maintenance Dose

Start date: September 2011
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the trial is to evaluate the efficacy of two dosing schedules of Avanz SQ+ (Standardised Quality) Phleum pratense compared to placebo in subjects with grass pollen induced allergic rhinoconjunctivitis with or without asthma.

NCT ID: NCT01438463 Completed - Allergic Rhinitis Clinical Trials

PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis

Start date: September 2011
Phase: Phase 2
Study type: Interventional

The objective of the present study is to characterize the dose-response relationship of PURETHAL® Mites with a nasal provocation test in order to support the optimal dose in terms of clinical efficacy and safety. For this purpose 5 groups of 50 patients, suffering from rhinitis or rhinoconjunctivitis due to House Dust Mite Allergy will be treated during 1 year. Before start, after 6 months of treatment and at the end of the study patients will be subjected to a nasal provocation test.

NCT ID: NCT01433510 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Tolerability of Grazax in Patients With Hayfever in Real Life Settings

GRAAL
Start date: November 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the safety profile of specific immunotherapy with Grazax for three consecutive grass pollen seasons.

NCT ID: NCT01085526 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Allergic Rhinitis

Start date: February 2010
Phase: N/A
Study type: Interventional

The trial is randomized prospective study to examine the effects of subcutaneous immunotherapy on the adaptive immune system. The trial includes 30 participants randomized to treatment or control group. The effect measures are changes in the basophil activity and biology as well as changes in plasma cells during and after treatment. Clinical outcome is assessed by QoL questionnaires and clinical testing. Hypotheses: - changes in plasma cells correlate to changes in immunoglobulins and effector cell responses - the reduction of inflammation due to SCIT has influence on the effector cell responses - changes in paraclinical measurements can be related to clinical findings